Affordable Access

Nabumetone in the treatment of skin and soft tissue injury.

Authors
Type
Published Article
Journal
The American Journal of Medicine
0002-9343
Publisher
Elsevier
Publication Date
Volume
83
Issue
4B
Pages
101–106
Identifiers
PMID: 3318420
Source
Medline
License
Unknown

Abstract

Nabumetone, a new nonsteroidal anti-inflammatory agent, has been evaluated for the treatment of skin and soft tissue injury, including sports injury, in clinical trials involving nearly 1,000 patients. Its efficacy, safety, and tolerance in these patients is reviewed. The efficacy of nabumetone in the treatment of soft tissue injury has been demonstrated to be similar to that of soluble aspirin, ibuprofen, and naproxen. It was not possible in these studies to demonstrate a definite advantage over placebo, and the reasons for this are discussed along with some suggestions for future studies. There were no serious adverse experiences reported, and nabumetone was well tolerated and compared favorably with the other agents used, including placebo. It caused significantly fewer gastrointestinal side effects than soluble aspirin. Nabumetone is an appropriate choice of nonsteroidal anti-inflammatory drug for the treatment of sports injury.

Statistics

Seen <100 times